These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30389217)

  • 21. PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
    Wang WG; Jiang XN; Sheng D; Sun CB; Lee J; Zhou XY; Li XQ
    Lab Invest; 2019 Oct; 99(10):1418-1427. PubMed ID: 31197205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus-positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
    Uccini S; Al-Jadiry MF; Scarpino S; Ferraro D; Alsaadawi AR; Al-Darraji AF; Moleti ML; Testi AM; Al-Hadad SA; Ruco L
    Hum Pathol; 2015 May; 46(5):716-24. PubMed ID: 25704629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
    Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
    Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
    Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age?
    Monabati A; Vahedi A; Safaei A; Noori S; Mokhtari M; Vahedi L; Zamani M
    Asian Pac J Cancer Prev; 2016; 17(4):2285-9. PubMed ID: 27221931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified.
    Hoffmann JC; Chisholm KM; Cherry A; Chen J; Arber DA; Natkunam Y; Warnke RA; Ohgami RS
    Hum Pathol; 2016 Feb; 48():9-17. PubMed ID: 26772393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review.
    Barzyk GA; Sheriff V
    Anticancer Res; 2020 Nov; 40(11):5951-5968. PubMed ID: 33109533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. pSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Teoh SH; Khoo JJ; Abdul Salam DSD; Peh SC; Cheah SC
    Malays J Pathol; 2019 Dec; 41(3):273-281. PubMed ID: 31901912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and immunohistochemical characterization of Epstein-Barr virus-associated diffuse large B-cell lymphoma.
    Al-Humood S; Alqallaf A; Al-Shemmari S; Al-Faris L; Al-Ayadhy B
    Acta Haematol; 2014; 131(1):1-10. PubMed ID: 24008861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
    Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
    Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas.
    Lima MA; Ferreira MV; Barros MA; Pardini MI; Ferrasi AC; Mota RM; Rabenhorst SH
    Diagn Mol Pathol; 2008 Jun; 17(2):82-9. PubMed ID: 18382371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
    Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of EBV-encoded small RNA targeted PCR to classify EBV positive diffuse large B-cell lymphoma (DLBCL) of the elderly.
    Lee J; Park M; Lee MH; Woo HJ; Kim HW; Yang JY; Eom YB; Kim SH; Yoo C; Kim JB
    Int J Clin Exp Pathol; 2015; 8(7):7859-68. PubMed ID: 26339350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
    Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
    PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].
    Xu FP; Liu YH; Zhuang HG; Luo DL; Li L; Zhang F; Luo XL; Du X; Li WY; Chen Q
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):616-21. PubMed ID: 22177246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma.
    Sun C; Jia Y; Wang W; Bi R; Wu L; Bai Q; Zhou X
    Histopathology; 2019 Mar; 74(4):618-628. PubMed ID: 30286249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.